Literature DB >> 26996391

One-hour post-load plasma glucose level during the OGTT predicts mortality: observations from the Israel Study of Glucose Intolerance, Obesity and Hypertension.

M Bergman1, A Chetrit2, J Roth3, R Dankner2,3,4.   

Abstract

AIMS: The relationship between 1- and 2-h glucose levels following an oral glucose tolerance test (OGTT) and long-term mortality was evaluated.
METHODS: Over a 33-year period, 2138 individuals were followed for all-cause mortality. Fasting and post-OGTT glucose parameters categorized the cohort according to baseline glycaemic status. Four categories were established according to 1- and 2-h glucose levels (in mmol/l): group A = 1 h ≤ 8.8 and 2 h < 7.8; group B = 1 h > 8.6 and 2 h < 7.8; group C = 1 h ≤ 8.6 and 2 h = 7.8-11.1 (impaired glucose tolerance); group D = 1 h > 8.6 and 2 h = 7.8-11.1 (impaired glucose tolerance). Individuals with diabetes at baseline were excluded from the cohort.
RESULTS: By August 2013, 51% of the study cohort had died. The worst prognosis occurred in group D (73.8% mortality), followed by groups C (67.5%), B and A (57.9% and 41.6%, respectively). When the 2-h glucose value is 'normal' (< 7.8 mmol/l), the 1-h glucose value > 8.6 mmol/l is an important predictor of mortality (28% increased risk) compared with group A, controlling for sex, age, smoking, BMI, systolic and diastolic blood pressures. A gradual increased hazard for mortality was seen by study group (hazard ratio = 1.28, 1.60 and 1.76, for groups B, C and D, respectively; group A = reference).
CONCLUSIONS: A 1-h glucose value > 8.6 mmol/l predicts mortality even when the 2-h level is < 7.8 mmol/l. However, when the 2-h level is in the impaired glucose tolerance range, the hazard for mortality rises significantly independent of the 1-h value. Individuals at risk for developing diabetes could be identified earlier using the 1-h threshold value of 8.6 mmol/l, which could avert progression to diabetes and increased mortality.‬.
© 2016 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26996391     DOI: 10.1111/dme.13116

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  16 in total

1.  Reducing the prevalence of dysglycemia: is the time ripe to test the effectiveness of intervention in high-risk individuals with elevated 1 h post-load glucose levels?

Authors:  Michael Bergman; Ram Jagannathan; Martin Buysschaert; Jose Luis Medina; Mary Ann Sevick; Karin Katz; Brenda Dorcely; Jesse Roth; Angela Chetrit; Rachel Dankner
Journal:  Endocrine       Date:  2017-01-25       Impact factor: 3.633

2.  One-hour and two-hour postload plasma glucose concentrations are comparable predictors of type 2 diabetes mellitus in Southwestern Native Americans.

Authors:  Ethan Paddock; Maximilian G Hohenadel; Paolo Piaggi; Pavithra Vijayakumar; Robert L Hanson; William C Knowler; Jonathan Krakoff; Douglas C Chang
Journal:  Diabetologia       Date:  2017-06-29       Impact factor: 10.122

3.  Elevated 1-h post-load plasma glucose is associated with right ventricular morphofunctional parameters in hypertensive patients.

Authors:  Angela Sciacqua; Maria Perticone; Sofia Miceli; Angelina Pinto; Velia Cassano; Elena Succurro; Francesco Andreozzi; Marta Letizia Hribal; Giorgio Sesti; Francesco Perticone
Journal:  Endocrine       Date:  2019-02-21       Impact factor: 3.633

4.  One-hour post-load plasma glucose levels associated with decreased insulin sensitivity and secretion and early makers of cardiometabolic risk.

Authors:  M L Marcovecchio; M Bagordo; E Marisi; T de Giorgis; V Chiavaroli; F Chiarelli; A Mohn
Journal:  J Endocrinol Invest       Date:  2017-03-01       Impact factor: 4.256

5.  Glucose patterns during an oral glucose tolerance test and associations with future diabetes, cardiovascular disease and all-cause mortality rate.

Authors:  Adam Hulman; Dorte Vistisen; Charlotte Glümer; Michael Bergman; Daniel R Witte; Kristine Færch
Journal:  Diabetologia       Date:  2017-10-06       Impact factor: 10.122

Review 6.  Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis.

Authors:  Vasudha Ahuja; Pasi Aronen; T A Pramodkumar; Helen Looker; Angela Chetrit; Aini H Bloigu; Auni Juutilainen; Cristina Bianchi; Lucia La Sala; Ranjit Mohan Anjana; Rajendra Pradeepa; Ulagamadesan Venkatesan; Sarvanan Jebarani; Viswanathan Baskar; Teresa Vanessa Fiorentino; Patrick Timpel; Ralph A DeFronzo; Antonio Ceriello; Stefano Del Prato; Muhammad Abdul-Ghani; Sirkka Keinänen-Kiukaanniemi; Rachel Dankner; Peter H Bennett; William C Knowler; Peter Schwarz; Giorgio Sesti; Rie Oka; Viswanathan Mohan; Leif Groop; Jaakko Tuomilehto; Samuli Ripatti; Michael Bergman; Tiinamaija Tuomi
Journal:  Diabetes Care       Date:  2021-04       Impact factor: 19.112

7.  Distinct metabolic profile according to the shape of the oral glucose tolerance test curve is related to whole glucose excursion: a cross-sectional study.

Authors:  Leonardo de Andrade Mesquita; Luciana Pavan Antoniolli; Giordano Fabricio Cittolin-Santos; Fernando Gerchman
Journal:  BMC Endocr Disord       Date:  2018-08-16       Impact factor: 2.763

Review 8.  Hyperglycemia at 1h-OGTT in Pregnancy: A Reliable Predictor of Metabolic Outcomes?

Authors:  Elena Succurro; Federica Fraticelli; Marica Franzago; Teresa Vanessa Fiorentino; Francesco Andreozzi; Ester Vitacolonna; Giorgio Sesti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555

Review 9.  Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus.

Authors:  Rajeev Chawla; Jagat Jyoti Mukherjee; Manoj Chawla; Alok Kanungo; Meenakshi Sundaram Shunmugavelu; Ashok Kumar Das
Journal:  Med Sci (Basel)       Date:  2021-05-28

10.  Type 2 diabetes and colorectal cancer survival: The multiethnic cohort.

Authors:  Yvette Amshoff; Gertraud Maskarinec; Yurii B Shvetsov; Phyllis H Raquinio; Andrew Grandinetti; Veronica W Setiawan; Christopher A Haiman; Loïc Le Marchand
Journal:  Int J Cancer       Date:  2018-02-25       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.